Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.77, read 2026-11-05
Ethical passes the values gate
Price13.84 USD
Fair value21.41
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-14Read Accumulation13.14+5.3% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown13.00+6.5% to today Distribution gives way to Markdown first Markdown read since July
2026-08-27Read Distribution12.98+6.6% to today Markdown gives way to Distribution after a 10% slide in 5 weeks
2026-07-26Read Markdown14.42-4.0% to today ✓Distribution gives way to Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Dole plc holds its Markup at $13.84. Consolidating, no directional conviction, held for 271 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 271 days
Price at the screen
$13.84
Valuation
18.70 trailing · 9.34 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.75
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
28.32%
Below 33%
Interest-bearing debt is just 28.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.15%
Below 33%
Cash held in interest-bearing accounts and securities is 0.1% of assets, under the one-third limit.
Pass
Receivables
21.64%
Below 49%
Money owed to the company is 21.6% of assets, under the 49% limit.
Pass
Revenue purity
0.15%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Dole clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 28%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when DOLE's ethical verdict changes
Today DOLE passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 35% discount to our $21.41 fair value, 2.90% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 35.4% discount to the base estimate.
Where our models see it going: fair-value estimate $21.41, with a range of $21.41 to $27.68, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Fresh fruit supply chains hide thin margins everywhere
Walk into any supermarket and the bananas and pineapples sit on the shelves as if they arrived without effort. Dole moves that produce from farms in Latin America and Africa through its three regional segments to shelves worldwide. Revenue is growing at 12 percent, yet the business posts a zero profit margin and an 8 percent return on equity.
The shares trade at a forward multiple of 9.7 times with a 48 percent gap to our fair value of $21.41. That gap looks tempting on paper, but zero margins and unknown competitive protection leave little room for error once input costs or weather shocks appear. Analyst targets sit at $17, offering scant support for the current price.
Currency swings, seasonal harvests and thin pricing power all sit inside an agricultural model that rarely compounds capital well. The ethical screen is clear, yet the operating numbers still fail to justify ownership today.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Ireland and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DOLE trades on the NYSE (the company is based in Ireland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Accumulation$13.08-3.3%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (4 analysts) rates it buy, with a mean price target of $18. Insiders have been net buyers over the past quarter.
2026-10-28Accumulation$13.52+0.8%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (4 analysts) rates it buy, with a mean price target of $18. Insiders have been net buyers over the past quarter.
2026-10-21Accumulation$13.41+2.1%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (4 analysts) rates it buy, with a mean price target of $18. Insiders have been net buyers over the past quarter.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (4 analysts) rates it buy, with a mean price target of $18.
2026-10-02Markdown · changed$13.00+0.2%Entry 6
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (4 analysts) rates it buy, with a mean price target of $18.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 10.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (4 analysts) rates it buy, with a mean price target of $18.
2026-07-26Markdown · changed$14.42+0.5%Entry 4
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (4 analysts) rates it buy, with a mean price target of $18.
2026-07-18Distribution$14.35+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (4 analysts) rates it buy, with a mean price target of $18.
2026-07-03Distribution$14.35+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Distribution$14.35Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
